S. Bangaru

发表

Structure and immune recognition of the porcine epidemic diarrhea virus spike protein

A. Ward, L. Sewall, R. Kirchdoerfer, 2020, bioRxiv.

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA

I. Wilson, S. Kent, J. Crowe, 2018, Nature Communications.

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

M. V. van Breemen, N. Kootstra, A. Ward, 2020, Science.

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

J. Diedrich, J. Yates, D. Nemazee, 2020, Science.

Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.

I. Wilson, J. Crowe, K. Edwards, 2019, Cell host & microbe.

Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.

I. Wilson, J. Crowe, H. Turner, 2019, Cell host & microbe.

Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

Peter D. Crompton, J. Mascola, I. Wilson, 2021, bioRxiv.

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

I. Wilson, N. Wu, A. Ward, 2020, Immunity.

Structural mapping of antibody landscapes to human betacoronavirus spike proteins

J. Crowe, J. Torres, L. Sewall, 2021, bioRxiv.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

M. Mulligan, W. Keitel, Shital M. Patel, 2015, The Journal of infectious diseases.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated In fl uenza A ( H 3 N 2 ) Variant Vaccine in Healthy Persons ≥ 18 Years Old

M. Mulligan, W. Keitel, Shital M. Patel, 2015 .

Human antibody recognition of H7N9 influenza virus HA following natural infection

H. Turner, A. Ward, S. Bangaru, 2021, JCI insight.

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses

A. Heck, R. Sanders, M. V. van Gils, 2023, iScience.

Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses

D. Burton, K. Kirsch, W. Schief, 2022, Immunity.

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Peter D. Crompton, J. Mascola, I. Wilson, 2021, Science Translational Medicine.

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

I. Wilson, N. Wu, A. Ward, 2020, Cell Reports.

Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity

I. Wilson, N. Wu, A. Ward, 2020, bioRxiv.

An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

I. Wilson, N. Wu, A. Ward, 2020, bioRxiv.

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

J. Diedrich, J. Yates, D. Nemazee, 2020, bioRxiv.

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains

I. Wilson, J. Pallesen, J. Crowe, 2018, bioRxiv.

A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface

I. Wilson, S. Kent, J. Crowe, 2019, Cell.

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

D. Burton, I. Wilson, N. Wu, 2021, Cell Host & Microbe.

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

I. Wilson, N. Wu, D. Nemazee, 2021, bioRxiv.

A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA

I. Wilson, S. Kent, J. Crowe, 2018, Nature Communications.

Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner

A. Ward, F. Krammer, S. Bangaru, 2021, bioRxiv.

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner

F. Krammer, S. Bangaru, L. Coughlan, 2021, mBio.

S. Bangaru, L. Coughlan, F. Amanat, 2021 .

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody

I. Wilson, N. Wu, D. Nemazee, 2020, bioRxiv.

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody

D. Burton, I. Wilson, N. Wu, 2020, PLoS pathogens.

H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.

I. Wilson, J. Crowe, M. Rock, 2016, The Journal of clinical investigation.

Prospective Study of Core Needle Biopsy on Bone Lesion

S. Bangaru, Dr. K. Durga, Dr. N. Vivekanand, 2018 .

Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes

D. Jaffe, D. Burton, M. Stubbington, 2023, bioRxiv.

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface

Cinque S. Soto, J. Crowe, Seth J. Zost, 2021, bioRxiv.

Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor binding head domains

I. Wilson, J. Pallesen, J. Crowe, 2018, bioRxiv.

Recognition of influenza H3N2 variant virus by human neutralizing antibodies.

R. Webby, J. Crowe, K. Edwards, 2016, JCI insight.

Increasing sensitivity of antibody-antigen interactions using photo-cross-linking

A. Shaw, S. Mohanty, C. Cottrell, 2023, Cell reports methods.

H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.

I. Wilson, J. Crowe, M. Rock, 2016, The Journal of clinical investigation.

Recognition of influenza H3N2 variant virus by human neutralizing antibodies.

R. Webby, J. Crowe, K. Edwards, 2016, JCI insight.